Linda A.’s Recent Stories
Health Jan 29Johnson & Johnson’ single-shot vaccine is 66 percent effective against COVID-19
With vaccinations off to a rocky start globally, experts had been counting on a one-dose vaccine that would stretch scarce supplies and avoid the logistics nightmare of getting people to return for boosters.
Health Oct 23AstraZeneca, Johnson & Johnson resume U.S. tests of COVID-19 vaccines
Two drugmakers say they have the go-ahead to resuming U.S. testing of their COVID-19 vaccine candidates. Both are in the final stage of testing before the companies can seek regulatory approval.
Health Sep 23Late-stage study of first single-shot vaccine begins in U.S.
Johnson & Johnson is beginning a huge final-stage study to try to prove if a single-dose COVID-19 vaccine can protect against the virus.
Health Aug 20Pandemic pushes expansion of ‘hospital-at-home’ treatment
Communications technology, portable medical equipment and teams of doctors, nurses, X-ray techs and paramedics make this possible. Like telemedicine, the concept stands to become more popular with consumers hooked on home delivery and other Internet-connected conveniences.
Health Aug 19FDA blocks much-anticipated BioMarin hemophilia gene therapy
Investors fled drug developer BioMarin in droves on Wednesday, driving shares down by a third after U.S. regulators rejected the company's potentially game-changing hemophilia A gene therapy.
Health Feb 28FDA reports drug shortage tied to novel coronavirus outbreak
The Food and Drug Administration declined to identify the manufacturer or the product.
Nation Dec 28Age limit now 21 across US for cigarettes, tobacco products
Anyone under 21 can no longer legally buy cigarettes, cigars or any other tobacco products in the U.S.
Politics Dec 19New trade deal presents landmark loss for Big Pharma
To satisfy House Democrats, the Trump administration removed a provision that would have given the makers of ultra-expensive biologic drugs 10 years of protection from less-expensive knockoffs.
Economy Dec 19Investors brace for market slowdown going into 2020 and beyond
Markets are coming off a fabulous 2019, where stocks and bonds around the world climbed in concert. But for the next year — and decade, in fact — Wall Street is telling investors to set their expectations considerably lower.
Health Nov 15U.S. approves new drug to manage sickle cell disease, costs $85,000 to $113,000
The monthly infusion, which halves occurrences of sickle cell pain episodes, will carry a list price of roughly $85,000 to $113,000 per year, depending on dosing. Insured patients generally will pay less.